Unknown PHASE2 INTERVENTIONAL 2-arm NCT03016715

Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study

A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)

Sponsor: Premier Specialists, Australia

Conditions Epidermolysis Bullosa Simplex Epidermolysis Bullosa Simplex Kobner Weber-Cockayne Syndrome

Interventions Sirolimus 2% Vehicle

Updated 6 times since 2017 Last updated: Oct 22, 2017 Started: May 31, 2016 Primary completion: Jun 30, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03016715, this PHASE2 trial focuses on Epidermolysis Bullosa Simplex and Epidermolysis Bullosa Simplex Kobner and remains ongoing. Sponsored by Premier Specialists, Australia, it has been updated 6 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Nov 2019 — Jan 2021 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jun 2018 — Nov 2019 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Feb 2017 — Jun 2018 [monthly]

Recruiting PHASE2

First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Premier Specialists, Australia

Data source: Premier Specialists, Australia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sydney, Australia